The formula was able to accurately group patients with luminal A and luminal B breast cancer according to prognosis (favorable or poor) but was not suitable for patients with basal-like, HER2+, and normal-like breast cancer (Fig. 5A–E). This evidence concerns the gene ERBB2 and breast carcinoma.